Research Article
BibTex RIS Cite

Clinical Features and Laboratory Values Associated with Disease Severity in Covid 19 Patients: A Single Center Experience

Year 2021, Volume: 4 Issue: 1, 18 - 22, 21.01.2021
https://doi.org/10.32322/jhsm.794659

Abstract

Background: To date, several studies were published about clinical features and laboratory values associated with disease severity in covid 19 patients. We aimed to show the relationship between disease severity and clinical and laboratory characteristics of the patients as a single center experience.
Methods: Clinical features and laboratory data of fifty patients diagnosed with Covid-19 by PCR was evaluated at diagnosis. These patients divided into 2 groups as early and advanced disease. Clinical features and laboratory data were compared in terms of severity of disease.
Results: In all patients, the most common accompanying disease was coronary artery disease. Cough and headache were the most common complaints. Laboratory values showed low lymphocyte count and high CRP levels in all patients. Twenty four patients in early stage and 26 patients in advanced stage were compared in terms of clinical features and laboratory values. In advanced stage, it was observed that body weight, number of comorbid diseases, age, CRP, procalcitonin, BUN, GGT, fibrinogen, D-dimer and ferritin levels of patients were higher whereas height, serum total protein, albumin and potassium levels were lower when compered with early stage patients (p <0.05).
Conclusions: Our data showed that older age, having cough, increased number of comorbid diseases, CRP, BUN, GGT, fibrinogen, D-dimer and ferritin and decresed serum total protein, albumin, potassium levels at the time of diagnosis in COVID-19 patients were associated with advanced stage disease.

References

  • Referans1 Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207.
  • Referans2 Pal M, Berhanu G, Desalegn C, et al. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020;12(3):7423.
  • Referans3 World Health Organization Press Conference. The World Health Organization (WHO) Has Officially Named the Disease Caused by the Novel Coronavirus as COVID-19. Available online: https://www.who.int/ emergencies/diseases/novel-coronavirus-2019 (accessed on 18 May 2020).
  • Referans4 Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523.
  • Referans5 Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China. 2019. N Engl J Med. 2020;382(8):727-733.
  • Referans6 Alfonso J. Rodriguez-Moralesa, Jaime A. Cardona-Ospina, Estefanía Gutiérrez-Ocampoa, Rhuvi Villamizar-Peñaa, Yeimer Holguin-Riveraa, Juan Pablo Escalera-Antezanai, et al. On behalf of the Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.
  • Referans7 Weiliang Cao, Li Shi, Lin Chen, Xuemei Xu, Zirong Wu. Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei.
  • Referans8 Yong Gao, Tuantuan Li, Mingfeng Han, Xiuyong Li, Dong Wu, Yuanhong Xu, Yulin Zhu, Yan Liu, Xiaowu Wang, Linding Wang. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
  • Referans9 Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577-582.
  • Referans10 Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College COVID-19 Response Team. 2020;10:77482.
  • Referans11 11. Gurbuz, P. COVID-19 and Diabetes Among Comorbidities: A Systematic.

Clinical features and laboratory values associated with disease severity in Covid 19 patients: a single center experience

Year 2021, Volume: 4 Issue: 1, 18 - 22, 21.01.2021
https://doi.org/10.32322/jhsm.794659

Abstract

Background: To date, several studies were published about clinical features and laboratory values associated with disease severity in covid 19 patients. We aimed to show the relationship between disease severity and clinical and laboratory characteristics of the patients as a single center experience.
Methods: Clinical features and laboratory data of fifty patients diagnosed with Covid-19 by PCR was evaluated at diagnosis. These patients divided into 2 groups as early and advanced disease. Clinical features and laboratory data were compared in terms of severity of disease.
Results: In all patients, the most common accompanying disease was coronary artery disease. Cough and headache were the most common complaints. Laboratory values showed low lymphocyte count and high CRP levels in all patients. Twenty four patients in early stage and 26 patients in advanced stage were compared in terms of clinical features and laboratory values. In advanced stage, it was observed that body weight, number of comorbid diseases, age, CRP, procalcitonin, BUN, GGT, fibrinogen, D-dimer and ferritin levels of patients were higher whereas height, serum total protein, albumin and potassium levels were lower when compered with early stage patients (p <0.05).
Conclusions: Our data showed that older age, having cough, increased number of comorbid diseases, CRP, BUN, GGT, fibrinogen, D-dimer and ferritin and decresed serum total protein, albumin, potassium levels at the time of diagnosis in COVID-19 patients were associated with advanced stage disease.

References

  • Referans1 Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207.
  • Referans2 Pal M, Berhanu G, Desalegn C, et al. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020;12(3):7423.
  • Referans3 World Health Organization Press Conference. The World Health Organization (WHO) Has Officially Named the Disease Caused by the Novel Coronavirus as COVID-19. Available online: https://www.who.int/ emergencies/diseases/novel-coronavirus-2019 (accessed on 18 May 2020).
  • Referans4 Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523.
  • Referans5 Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China. 2019. N Engl J Med. 2020;382(8):727-733.
  • Referans6 Alfonso J. Rodriguez-Moralesa, Jaime A. Cardona-Ospina, Estefanía Gutiérrez-Ocampoa, Rhuvi Villamizar-Peñaa, Yeimer Holguin-Riveraa, Juan Pablo Escalera-Antezanai, et al. On behalf of the Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.
  • Referans7 Weiliang Cao, Li Shi, Lin Chen, Xuemei Xu, Zirong Wu. Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei.
  • Referans8 Yong Gao, Tuantuan Li, Mingfeng Han, Xiuyong Li, Dong Wu, Yuanhong Xu, Yulin Zhu, Yan Liu, Xiaowu Wang, Linding Wang. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
  • Referans9 Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577-582.
  • Referans10 Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College COVID-19 Response Team. 2020;10:77482.
  • Referans11 11. Gurbuz, P. COVID-19 and Diabetes Among Comorbidities: A Systematic.
There are 11 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Original Article
Authors

Nurcan Kırıcı Berber 0000-0001-8634-2543

Özkan Ulutaş 0000-0002-2155-8340

Ahmet Sarıcı 0000-0002-5916-0119

Aslı Yıldırım 0000-0003-3226-2972

Özlem Çağaşar This is me 0000-0002-6995-086X

Harika Gözükara This is me 0000-0003-1208-4072

İlhami Berber 0000-0003-3312-8476

Publication Date January 21, 2021
Published in Issue Year 2021 Volume: 4 Issue: 1

Cite

AMA Kırıcı Berber N, Ulutaş Ö, Sarıcı A, Yıldırım A, Çağaşar Ö, Gözükara H, Berber İ. Clinical features and laboratory values associated with disease severity in Covid 19 patients: a single center experience. J Health Sci Med / JHSM. January 2021;4(1):18-22. doi:10.32322/jhsm.794659

Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].

The Directories (indexes) and Platforms we are included in are at the bottom of the page.

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show







The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.

       images?q=tbn:ANd9GcRB9r6zRLDl0Pz7om2DQkiTQXqDtuq64Eb1Qg&usqp=CAU

500px-WorldCat_logo.svg.png

atifdizini.png

logo_world_of_journals_no_margin.png

images?q=tbn%3AANd9GcTNpvUjQ4Ffc6uQBqMQrqYMR53c7bRqD9rohCINkko0Y1a_hPSn&usqp=CAU

doaj.png  

images?q=tbn:ANd9GcSpOQFsFv3RdX0lIQJC3SwkFIA-CceHin_ujli_JrqBy3A32A_Tx_oMoIZn96EcrpLwTQg&usqp=CAU

ici2.png

asos-index.png

drji.png





The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.

COPE-logo-300x199.jpgimages?q=tbn:ANd9GcQR6_qdgvxMP9owgnYzJ1M6CS_XzR_d7orTjA&usqp=CAU

icmje_1_orig.png

cc.logo.large.png

ncbi.pngimages?q=tbn:ANd9GcRBcJw8ia8S9TI4Fun5vj3HPzEcEKIvF_jtnw&usqp=CAU

ORCID_logo.png

1*mvsP194Golg0Dmo2rjJ-oQ.jpeg


Our Journal using the DergiPark system indexed are;

Ulakbim TR Dizin,  Index Copernicus, ICI World of JournalsDirectory of Research Journals Indexing (DRJI), General Impact FactorASOS Index, OpenAIRE, MIAR,  EuroPub, WorldCat (OCLC)DOAJ,  Türkiye Citation Index, Türk Medline Index, InfoBase Index


Our Journal using the DergiPark system platforms are;

Google, Google Scholar, CrossRef (DOI), ResearchBib, ICJME, COPE, NCBI, ORCID, Creative Commons, Open Access, and etc.


Journal articles are evaluated as "Double-Blind Peer Review". 

Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user.  https//dergipark.org.tr/tr/pub/jhsm/page/9535

Journal charge policy   https://dergipark.org.tr/tr/pub/jhsm/page/10912


Editor List for 2022

Assoc. Prof. Alpaslan TANOĞLU (MD)  

Prof. Aydın ÇİFCİ (MD)

Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)

Prof. Murat KEKİLLİ (MD)

Prof. Yavuz BEYAZIT (MD) 

Prof. Ekrem ÜNAL (MD)

Prof. Ahmet EKEN (MD)

Assoc. Prof. Ercan YUVANÇ (MD)

Assoc. Prof. Bekir UÇAN (MD) 

Assoc. Prof. Mehmet Sinan DAL (MD)


Our journal has been indexed in DOAJ as of May 18, 2020.

Our journal has been indexed in TR-Dizin as of March 12, 2021.


17873

Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.